Navigation Links
NVA237 Phase III GLOW2 Data at American Thoracic Society (ATS) International Conference and Phase II Clinical Trial Update
Date:5/16/2012

ver a 24-hour period compared to placebo with a fast onset of action at first dose, as well as improving exercise endurance. It was submitted for regulatory approval in Europe in Q3 2011 and Japan in Q4 2011, and expected US filing is in the beginning of 2014. NVA237 was licensed to Novartis in April 2005 by Sosei and our co-development partner Vectura.

Indacaterol (Onbrez® Breezhaler®) is Novartis' once daily long acting beta2-agonist (LABA). Novartis received European regulatory approval for 150 mcg and 300 mcg once-daily doses, under the brand name Onbrez® Breezhaler® in November 2009. In July 2011, Novartis announced approval of the 75 mcg once-daily dose in the US under the brand name Arcapta™ Neohaler™, and of the 150 mcg once-daily dose in Japan under the brand name Onbrez® Inhalation Capsules.

QVA149 (indacaterol 110 mcg/glycopyrronium bromide 50 mcg) is an investigational inhaled, once-daily, fixed dose combination of the long acting beta2-agonist (LABA) indacaterol, and the long-acting muscarinic antagonist (LAMA) glycopyrronium bromide (NVA237). The first four QVA149 Phase III studies in the treatment of COPD all met their primary endpoints. The results of the SHINE, BRIGHT, ENLIGHTEN and ILLUMINATE studies, which are key components of the IGNITE program, demonstrate the potential of QVA149 in the treatment of COPD. Filing for QVA149 in Europe is expected in Q4 2012.

About COPD

COPD is a progressive disease associated mainly with tobacco smoking, air pollution or occupational exposure, which can cause obstruction of airflow in the lungs resulting in debilitating bouts of breathlessness. It affects an estimated 210 million people worldwide[1]and is predicted to be the third leading cause of death by 2020[2]. Although COPD is often thought of as a disea
'/>"/>

SOURCE Sosei Group Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. NVA237 Filed in Europe and Positive Phase III Data at European Respiratory Society Congress
2. Phase III Study Shows Once-Daily NVA237 is Superior to Placebo and Similar to Tiotropium in Improving Lung Function in COPD
3. Sosei and Vectura Announce Start of Phase III Clinical Study With NVA237
4. NVA237 Phase II Results Presented at the European Respiratory Society Annual Meeting Show Promising Efficacy and Tolerability With Potentially Faster Onset Than Tiotropium
5. Boehringer Ingelheim to present pivotal Phase III results for afatinib in first-line treatment of EGFR mutation-positive NSCLC at ASCO 2012
6. Inovio Pharmaceuticals Universal Avian Flu Vaccine Generates Protective Antibody Responses Against Six H5N1 Viruses in Phase I Trial
7. Novelos Therapeutics Successfully Completes First Cohort In Phase 1b Solid Tumor Trial With I-131-CLR1404 (HOT) Cancer-Targeted Molecular Radiotherapeutic
8. Adamas Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA for Arimenda™
9. Pearl Therapeutics Phase 2b Twice-Daily Dosing Data Suggest Morning and Evening Benefit of PT003 in Patients with COPD
10. Results Reported for Phase Ib Open-Label Clinical Trial for the Treatment of Depression Using External Trigeminal Nerve Stimulation (eTNS™) - The USB Port to the Brain™
11. Alder BioPharmaceuticals Inc. Initiates Phase 1 Clinical Study of Antibody Therapeutic Candidate for Treatment of Migraine, ALD403
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... , Nov. 26, 2014  Genomic Health, Inc. (Nasdaq: ... , Chairman, Chief Executive Officer and President, will participate ... Conference at The New York Palace Hotel in ... at 11:30 am Eastern Time (ET). To ... conference call, go to the  Investor Relations  section of ...
(Date:11/26/2014)... , November 26, 2014 Investor-Edge ... VVUS ), Horizon Pharma PLC (NASDAQ: ... and Johnson (NYSE: JNJ ), and Theravance Inc. ... companies can be accessed at: http://investor-edge.com/register . ... 4,758.25, up 0.07%, the Dow Jones Industrial Average edged 0.02% ...
(Date:11/26/2014)... 2014  CARsgen, a leader in the development of ... a variety of cancers, today announced the completion of ... China -based healthcare private equity fund.   ... the development of new therapeutics for liver, lung, stomach ... and Shanghai Renji Hospital, the company plans to initiate ...
Breaking Medicine Technology:Genomic Health to Present at the 26th Annual Piper Jaffray Healthcare Conference 2Genomic Health to Present at the 26th Annual Piper Jaffray Healthcare Conference 3Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 2Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 3Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 4Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 5CARsgen Completes Series A Financing 2
... cell company,Neuralstem, Inc., (Amex: CUR ) announced ... a European patent EP0915968, covering the,"Isolation, Propagation and ... Central Nervous System of Mammals." The European patent,has ... Germany,Ireland, Spain, Sweden, Switzerland and the United Kingdom., ...
... In Migraine Pain ... 48 Hours Vs. Placebo, MENLO PARK, Calif., April ... from a clinical study of the company,s,novel investigational intranasal ... The placebo-controlled proof of concept study evaluated the ...
Cached Medicine Technology:Neuralstem Announces Issuance of Core Technology Patent in Europe 2ROXRO PHARMA Announces Positive Clinical Proof of Concept Results for Novel Intranasal Migraine Treatment 2ROXRO PHARMA Announces Positive Clinical Proof of Concept Results for Novel Intranasal Migraine Treatment 3
(Date:11/28/2014)... Mabel’s Labels , the market ... an award-winning company established by four moms, today announced ... Tricia Mumby have been honored with a 2014 RBC ... PROFIT Award for Excellence in Entrepreneurship. , All 4 ... Mumby) accepted the award on behalf of Mabel’s Labels ...
(Date:11/28/2014)... 28, 2014 UniWigs.com, a leader in the wig ... Friday to the next Monday. This promotion features: , ... 40 items up to 70% off (no coupon code needed), ... > Free shipping on orders over $49 , Visit http://www.uniwigs.com ... days from Nov. 28th to Dec. 1st and the first 100 ...
(Date:11/28/2014)... (PRWEB) November 28, 2014 "Most of my ... me to use crutches," said an inventor from Findlay, Ohio. ... convenient way to support my foot, which inspired me to ... to offer a convenient way to support an injured foot. ... around. It eliminates the need for crutches. The design redistributes ...
(Date:11/28/2014)... November 28, 2014 Before that Thanksgiving meal ... preparing for the Christmas shopping season. Today, people will stand ... Black Friday, the biggest retail shopping day of the year. ... electronic device, New Albany dentist Dr. Ronald Receveur ... improve oral health and literally brighten a few smiles. , ...
(Date:11/28/2014)... 2014 Most of the people attending a ... at Lake Prince Woods retirement community found out ... sentimental value but wouldn’t have made the cut to be ... his expertise in decorative and folk art and his appearances ... about trends in buying and selling antiques. Broadly speaking ...
Breaking Medicine News(10 mins):Health News:Mabel's Labels’ Co-Founders Named A Winner In The 2014 RBC Canadian Women Entrepreneur Awards Program; A Second-Time Win For The Brand 2Health News:Mabel's Labels’ Co-Founders Named A Winner In The 2014 RBC Canadian Women Entrepreneur Awards Program; A Second-Time Win For The Brand 3Health News:Pre-X'mas Crazy Sale Starts from $0 at UniWigs.com 2Health News:New Albany Dentist Offers Gift Ideas That Can Improve Oral Health 2Health News:New Albany Dentist Offers Gift Ideas That Can Improve Oral Health 3Health News:New Albany Dentist Offers Gift Ideas That Can Improve Oral Health 4Health News:Antiques Appraiser Sheds Light on "Treasures" 2
... Effective Means to Provide Health Care Access to Millions ... The National Patient Advocate Foundation (NPAF) - a national, ... of improved patient access to health care through public ... announced this month the election of four new Executive ...
... possibility of remote monitoring for chronically ill patients will ... and Australia have devised a decentralized system to avoid ... a forthcoming issue of the International Journal of ... range of chronic illnesses, including diabetes, high blood pressure, ...
... Health Care Reform, Received More Industry Contributions Than ... and pharmaceutical manufacturers contributed $5.5 million to the ... House of Representatives during the last two election ... reform dominated political discourse, according to the nonprofit, ...
... Petfinder.com and Merial Team Up to Ensure Animal Welfare ... 9 Petfinder.com, the largest online database of adoptable ... generators to 500 shelters and rescue groups nationwide with ... to the Paws program, a disaster preparedness initiative launched ...
... with chemo and radiation , , MONDAY, March 9 ... chemotherapy drug temozolomide and radiotherapy increases survival for glioblastoma ... improvement persists for up to five years, say Swiss ... aggressive form of primary brain tumor. For more than ...
... DALLAS, March 9 Inspired by Beryl Co-Founder Barry Spiegelman ... The Beryl Institute is hosting the second annual ... at Sky Creek Ranch Golf Club in Keller, Texas. To ... the tournament will be presented to UCLA,s Neuro-Oncology Program, ...
Cached Medicine News:Health News:National Patient Advocate Foundation Announces 2009 Elections of Health Policy Leaders to Executive Board of Directors 2Health News:National Patient Advocate Foundation Announces 2009 Elections of Health Policy Leaders to Executive Board of Directors 3Health News:National Patient Advocate Foundation Announces 2009 Elections of Health Policy Leaders to Executive Board of Directors 4Health News:National Patient Advocate Foundation Announces 2009 Elections of Health Policy Leaders to Executive Board of Directors 5Health News:National Patient Advocate Foundation Announces 2009 Elections of Health Policy Leaders to Executive Board of Directors 6Health News:National Patient Advocate Foundation Announces 2009 Elections of Health Policy Leaders to Executive Board of Directors 7Health News:National Patient Advocate Foundation Announces 2009 Elections of Health Policy Leaders to Executive Board of Directors 8Health News:Peer-to-peer heart monitoring 2Health News:Consumer Watchdog: Health Insurers & Drug Companies Contributed $5.5 Million to Top 10 Senate and House Recipients Since 2005 2Health News:Consumer Watchdog: Health Insurers & Drug Companies Contributed $5.5 Million to Top 10 Senate and House Recipients Since 2005 3Health News:Consumer Watchdog: Health Insurers & Drug Companies Contributed $5.5 Million to Top 10 Senate and House Recipients Since 2005 4Health News:Consumer Watchdog: Health Insurers & Drug Companies Contributed $5.5 Million to Top 10 Senate and House Recipients Since 2005 5Health News:Petfinder.com Foundation 'Rescues' 500 Shelters and Rescue Groups Nationwide with $1 Million Worth of Generators 2Health News:Combo Treatment for Aggressive Brain Tumor May Lengthen Life 2Health News:Think About It. Barry Spiegelman Memorial Golf Classic Benefits Brain Cancer Research 2
20 g MVR knife. Dimensions: 31.8 mm x 1.18 mm x 2.7 mm....
Full Handle Laseredge Spoon Blade Knife, 3.0 mm angled double bevel. Blade dimension: 11.0 mm (L) x 3.0 mm (W). Cut: 320....
Full Handle Laseredge Slit Blade Knife, 3.2 mm angled double bevel. Blade tip dimension: 14.4 mm x 3.2 mm x 4.0 mm....
Full Handle Laseredge Slit Blade Knife, 3.0 mm angled bevel up. Blade tip dimension: 14.4 mm x 3.0 mm x 3.7 mm....
Medicine Products: